ADAPY

SEC source: 0001209191-20-039805 · doc4.xml · derivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,258

Underlying: Ordinary Shares · 184,258 shares

Expires 2030-07-01

F1 · derivative.exercise_price: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-20-079786 · a4.xml · derivative · entry 1

Sigal Charles Elliott · CIK 0001661908 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,258

Underlying: Ordinary Shares · 184,258 shares

Expires 2030-07-02

F1 · derivative.exercise_price: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-20-079248 · a4.xml · nonDerivative · entry 1

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,000

F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.

F2 · shares: The 33,000 ordinary shares reported in Column 4 are represented by 5,500 ADSs.

F3 · price: The price reported in Column 4 of $1.62 per ordinary share is derived from the purchase price paid on June 29, 2020 of $9.7497 per ADS divided by six.

SEC source: 0001104659-20-072556 · a4.xml · nonDerivative · entry 1

Alleva Lawrence M · CIK 0001553053 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Trust

Disclosed balance after: 12,900

F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Lawrence M. Alleva Revocable Trust. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.

F2 · shares: The 12,900 ordinary shares reported in Column 4 and Column 5 are represented by 2,150 ADSs.

F3 · price: The price reported in Column 4 of $1.89 per ordinary share is derived from the purchase price paid on June 9, 2020 of $11.354 per ADS divided by six.

F2 · balance_after: The 12,900 ordinary shares reported in Column 4 and Column 5 are represented by 2,150 ADSs.

SEC source: 0001104659-20-069142 · a4.xml · nonDerivative · entry 1

Noble James · CIK 0001388000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019.

F3 · shares: The ADSs reported in this Column 4 represent solely those ADSs that were sold pursuant to a Rule 10b5-1 trading plan. Additionally, the reporting person holds 8,145,700 ordinary shares and share options covering an aggregate of 9,137,960 ordinary shares of the Issuer.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $9.02 to $10.13, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote.

SEC source: 0001104659-20-042013 · a4.xml · derivative · entry 1

Noble James · CIK 0001388000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,000

Underlying: Ordinary Shares · 31,000 shares

Expires 2030-04-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.36 based on an exchange rate of $U.S. 1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-20-042012 · a4.xml · derivative · entry 2

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 565,000

Underlying: Ordinary Shares · 565,000 shares

Expires 2030-04-01

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 141,250 Ordinary Shares on April 1, 2021 and will be exercisable as to the remainder in annual installments of 141,250 Ordinary Shares on the first of each April from April 1, 2022 through April 1, 2024.

SEC source: 0001104659-20-042012 · a4.xml · derivative · entry 1

Wood Gavin · CIK 0001577539 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500,000

Underlying: Ordinary Shares · 2,500,000 shares

Expires 2030-04-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.36 based on an exchange rate of U.S.$1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 625,000 Ordinary Shares on April 1, 2021 and will be exercisable as to the remainder in monthly installments of 52,080 Ordinary Shares on the first of each month from May 1, 2021 through March 1, 2024 and 52,200 Ordinary Shares on April 1, 2024.

SEC source: 0001209191-20-005164 · doc4.xml · nonDerivative · entry 1

BASKETT FOREST · CIK 0001277631 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 3

Disclosed balance after: 19,500,000

F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F2 · price: The price reported in Column 4 of $0.6667 per ordinary share is a price derived from the price of $4.00 per ADS, divided by six.

F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F3 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

SEC source: 0001209191-20-005172 · doc4.xml · nonDerivative · entry 1

SANDELL SCOTT D · CIK 0001237289 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 3

Disclosed balance after: 19,500,000

F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F2 · price: The price reported in Column 4 of $0.6667 per ordinary share is a price derived from the price of $4.00 per ADS, divided by six.

F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F3 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

SEC source: 0001209191-20-005170 · doc4.xml · nonDerivative · entry 1

MOTT DAVID M · CIK 0001219871 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 3

Disclosed balance after: 19,500,000

F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F2 · price: The price reported in Column 4 of $0.6667 per ordinary share is a price derived from the price of $4.00 per ADS, divided by six.

F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F3 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

SEC source: 0001209191-20-005168 · doc4.xml · nonDerivative · entry 1

Florence Anthony A. Jr. · CIK 0001559827 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 3

Disclosed balance after: 19,500,000

F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F2 · price: The price reported in Column 4 of $0.6667 per ordinary share is a price derived from the price of $4.00 per ADS, divided by six.

F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F3 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

SEC source: 0001209191-20-005173 · doc4.xml · nonDerivative · entry 1

Sonsini Peter W. · CIK 0001559807 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 3

Disclosed balance after: 19,500,000

F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F2 · price: The price reported in Column 4 of $0.6667 per ordinary share is a price derived from the price of $4.00 per ADS, divided by six.

F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F3 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

SEC source: 0001209191-20-005167 · doc4.xml · nonDerivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note 3

Disclosed balance after: 19,500,000

F1 · security: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F1 · shares: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F2 · price: The price reported in Column 4 of $0.6667 per ordinary share is a price derived from the price of $4.00 per ADS, divided by six.

F1 · balance_after: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F3 · ownership.nature: The Reporting Person is a manager of NEA 16 GP, LLC, ("NEA 16 GP") which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

SEC source: 0001104659-20-005258 · a4.xml · derivative · entry 2

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,896

Underlying: Ordinary Shares · 280,896 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 70,224 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on January 16, 2022 and January 16, 2023 and 70,224 Ordinary Shares on January 16, 2024.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-20-005258 · a4.xml · derivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,257,744

Underlying: Ordinary Shares · 1,257,744 shares

Expires 2030-01-16

F1 · derivative.exercise_price: The exercise price was converted from GBP0.57 based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 314,436 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the sixteenth of each month from February 16, 2021 through December 16, 2023 and 26,238 Ordinary Shares on January 16, 2024.

SEC source: 0001104659-20-005256 · a4.xml · derivative · entry 2

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 561,792

Underlying: Ordinary Shares · 561,792 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 140,448 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 140,448 Ordinary Shares on the sixteenth of each January from January 16, 2022 through January 16, 2024.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-20-005256 · a4.xml · derivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,515,536

Underlying: Ordinary Shares · 2,515,536 shares

Expires 2030-01-16

F1 · derivative.exercise_price: The exercise price was converted from GBP0.57 based on an exchange rate of $U.S. 1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 628,884 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 52,404 Ordinary Shares on the sixteenth of each month from February 16, 2021 through December 16, 2023 and 52,512 Ordinary Shares on January 16, 2024.

SEC source: 0001104659-20-005263 · a4.xml · derivative · entry 2

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,600

Underlying: Ordinary Shares · 135,600 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1. 302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 33,900 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 33,900 Ordinary Shares on the sixteenth of each January from January 16, 2022 through January 16, 2024.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-20-005263 · a4.xml · derivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,600

Underlying: Ordinary Shares · 201,600 shares

Expires 2030-01-16

F1 · derivative.exercise_price: The exercise price was converted from GBP0.57 based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 50,400 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 4,200 Ordinary Shares on the sixteenth of each month from February 16, 2021 through January 16, 2024.

SEC source: 0001104659-20-005261 · a4.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,896

Underlying: Ordinary Shares · 280,896 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 70,224 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on the sixteenth of each January from January 16, 2022 through January 16, 2024.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-20-005261 · a4.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,257,744

Underlying: Ordinary Shares · 1,257,744 shares

Expires 2030-01-16

F1 · derivative.exercise_price: The exercise price was converted from GBP0.57 based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 314,436 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the sixteenth of each month from February 16, 2021 through December 16, 2023 and 26,238 Ordinary Shares on January 16, 2024.

SEC source: 0001104659-20-005262 · a4.xml · derivative · entry 2

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,896

Underlying: Ordinary Shares · 280,896 shares

Expires 2030-01-16

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S 1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 70,224 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in annual installments of 70,224 Ordinary Shares on January 16, 2022 and January 16, 2023, and 70,224 Ordinary Shares on January 16, 2024.

SEC source: 0001104659-20-005262 · a4.xml · derivative · entry 1

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,257,744

Underlying: Ordinary Shares · 1,257,744 shares

Expires 2030-01-16

F1 · derivative.exercise_price: The exercise price was converted from GBP0.57 based on an exchange rate of U.S$1.302659 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 314,436 Ordinary Shares on January 16, 2021 and will be exercisable as to the remainder in monthly installments of 26,202 Ordinary Shares on the sixteenth of each month from February 16, 2021 through December 16, 2023 and 26,238 Ordinary Shares on January 16, 2024.

SEC source: 0001104659-20-004423 · a4.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,605

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.12 to $5.18, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 9,363ADSs and RSU-style options and other options covering an aggregate of 5,299,674 ordinary shares of the Issuer.

SEC source: 0001104659-20-004420 · a4.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,166

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.12 to $5.18, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 9,122 ADSs and RSU-style options and other options covering an aggregate of 9,784,788 ordinary shares of the Issuer.

SEC source: 0001104659-20-004424 · a4.xml · nonDerivative · entry 1

Norry Elliot · CIK 0001798117 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,326

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.12 to $5.18, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 2,679 ADSs and RSU-style options and other options covering an aggregate of 789,782 ordinary shares of the Issuer.

SEC source: 0001104659-20-004421 · a4.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,681

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.12 to $5.18, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 6,478 ADSs and RSU-style options and other options covering an aggregate of 2,136,708 ordinary shares of the Issuer.

SEC source: 0001104659-20-004419 · a4.xml · nonDerivative · entry 2

Noble James · CIK 0001388000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019.

F3 · price: These ADSs were sold in multiple transactions at a price of $5.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote.

SEC source: 0001104659-20-004419 · a4.xml · nonDerivative · entry 1

Noble James · CIK 0001388000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019.

F2 · price: These ADSs were sold in multiple transactions at a price of $4.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote.

SEC source: 0001104659-20-004422 · a4.xml · nonDerivative · entry 2

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019.

F3 · price: These ADSs were sold in multiple transactions at a price of $5.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote.

SEC source: 0001104659-20-004422 · a4.xml · nonDerivative · entry 1

TAYTON-MARTIN HELEN KATRINA · CIK 0001661780 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019.

F2 · price: These ADSs were sold in multiple transactions at a price of $4.00. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at this price in this footnote.

SEC source: 0001104659-20-002081 · a4.xml · nonDerivative · entry 1

Bertrand William C JR · CIK 0001291937 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,632

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.20 to $1.2008, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 3,731 ADSs and RSU-style options and other options covering an aggregate of 5,335,686 ordinary shares of the Issuer

SEC source: 0001104659-20-002080 · a4.xml · nonDerivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,804

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.20 to $1.2008, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 3,318 ADSs and RSU-style options and other options covering an aggregate of 9,823,200 ordinary shares of the Issuer.

SEC source: 0001104659-20-002082 · a4.xml · nonDerivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,677

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2020. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $1.20 to $1.2008, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 4,801 ADSs and RSU-style options and other options covering an aggregate of 2,153,658 ordinary shares of the Issuer.

SEC source: 0001104659-19-048518 · a4.xml · derivative · entry 2

Rawcliffe Adrian · CIK 0001555851 · Director · CEO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,448

Underlying: Ordinary Shares · 140,448 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.21721 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 35,112 Ordinary Shares on September 1, 2020 and will be exercisable as to the remainder in annual installments of 35,112 Ordinary Shares on the first of each September from September 1, 2021 through September 1, 2023.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-19-048518 · a4.xml · derivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Director · CEO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 628,872

Underlying: Ordinary Shares · 628,872 shares

Expires 2029-09-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.22 based on an exchange rate of $U.S. 1.21721 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 157,218 Ordinary Shares on September 1, 2020 and will be exercisable as to the remainder in monthly installments of 13,101 Ordinary Shares on the first of each month from October 1, 2020 through August 1, 2023 and 13,119 Ordinary Shares on September 1, 2023.

SEC source: 0001104659-19-044630 · a4.xml · nonDerivative · entry 1

Amado Rafael · CIK 0001662119 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,237

F1 · security: Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on August 6, 2018 and which vested on August 6, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $2.02 to $2.085, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 20,974 ADSs and RSU-style options and other options covering an aggregate of 9,356,928 ordinary shares of the Issuer.

SEC source: 0001104659-19-044061 · a4.xml · derivative · entry 2

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Ordinary Shares · 187,500 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.22179 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 46,875 Ordinary Shares on August 1, 2020 and will be exercisable as to the remainder in annual installments of 46,875 Ordinary Shares on the first of each August from August 1, 2021 through August 1, 2023.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-19-044061 · a4.xml · derivative · entry 1

Lunger John · CIK 0001784487 · Chief Patient Supply Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 839,568

Underlying: Ordinary Shares · 839,568 shares

Expires 2029-08-01

F1 · derivative.exercise_price: The exercise price was converted from GBP0.45 based on an exchange rate of U.S.$1.22179 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 209,892 Ordinary Shares on August 1, 2020 and will be exercisable as to the remainder in monthly installments of 17,490 Ordinary Shares on the first of each month from September 1, 2020 through July 1, 2023 and 17,526 Ordinary Shares on August 1, 2023.

SEC source: 0001104659-19-039324 · a4.xml · derivative · entry 1

Furey John · CIK 0001691218 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,541

Underlying: Ordinary Shares · 240,541 shares

Expires 2029-07-02

F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-19-039327 · a4.xml · derivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,000

Underlying: Ordinary Shares · 124,000 shares

Expires 2029-07-02

F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-19-039323 · a4.xml · derivative · entry 1

Kerr Giles Francis Bertram · CIK 0001689112 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,000

Underlying: Ordinary Shares · 124,000 shares

Expires 2029-07-02

F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-19-039322 · a4.xml · derivative · entry 1

Duncan Barbara Gayle · CIK 0001353128 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,000

Underlying: Ordinary Shares · 124,000 shares

Expires 2029-07-02

F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001209191-19-041241 · doc4.xml · derivative · entry 1

MOTT DAVID M · CIK 0001219871 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,947

Underlying: Ordinary Shares · 350,947 shares

Expires 2029-07-02

F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-19-039321 · a4.xml · derivative · entry 1

Alleva Lawrence M · CIK 0001553053 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 271,209

Underlying: Ordinary Shares · 271,209 shares

Expires 2029-07-02

F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001209191-19-041239 · doc4.xml · derivative · entry 1

Behbahani Ali · CIK 0001613867 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 234,407

Underlying: Ordinary Shares · 234,407 shares

Expires 2029-07-02

F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-19-039326 · a4.xml · derivative · entry 1

Sigal Charles Elliott · CIK 0001661908 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 234,407

Underlying: Ordinary Shares · 234,407 shares

Expires 2029-07-02

F1 · derivative.exercise_price: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount.

SEC source: 0001104659-19-038003 · a4.xml · derivative · entry 2

Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,448

Underlying: Ordinary Shares · 140,448 shares

Expires not disclosed

F3 · derivative.exercise_price: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.26828 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F4 · derivative.exercise_date: Exercisable as to 35,112 Ordinary Shares on June 27, 2020 and will be exercisable as to the remainder in annual installments of 35,112 Ordinary Shares on the twenty-seventh of each June from June 27, 2021 through June 27, 2023.

F5 · derivative.expiration_date: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

SEC source: 0001104659-19-038003 · a4.xml · derivative · entry 1

Rawcliffe Adrian · CIK 0001555851 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 628,872

Underlying: Ordinary Shares · 628,872 shares

Expires 2029-06-27

F1 · derivative.exercise_price: The exercise price was converted from GBP0.53 based on an exchange rate of $U.S. 1.26828 - GBP1.00. The actual exercise price will be the pounds sterling amount.

F2 · derivative.exercise_date: Exercisable as to 157,218 Ordinary Shares on June 27, 2020 and will be exercisable as to the remainder in monthly installments of 13,101 Ordinary Shares on the twenty-seventh of each month from July 27, 2020 through May 27, 2022 and 13,119 Ordinary Shares on June 27, 2023.